BioCentury
ARTICLE | Financial News

Roivant, now valued at $7B, raises $200M in equity financing

November 16, 2018 3:55 PM UTC

Roivant Sciences GmbH (Basel, Switzerland) raised $200 million in its fourth equity financing on Nov. 13, which Roivant says values the company at about $7 billion. New investors NovaQuest Capital Management and RTW Investments joined existing investors Founders Fund, SoftBank, Viking, QVT and Dexcel in the round. Additional undisclosed new investors also participated.

Roivant plans to use the financing to launch additional subsidiaries, called “vants.” To date, Roivant has launched 14 vants across multiple therapeutic areas. The company’s urology play Urovant Sciences Ltd. (NASDAQ:UROV) raised $140 million in an IPO this year (see “Urovant Raises $140 Million IPO”)...

BCIQ Company Profiles

Roivant Sciences Ltd.